Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B5PV
|
|||
| Drug Name |
CART-EGFRvIII T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [1] | |
| Glioma [ICD-11: 2A00.0; ICD-9: 191] | Clinical trial | [2] | ||
| Company |
University of Pennsylvania
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Epidermal growth factor receptor variant III (EGFR vIII) | Target Info | CAR-T-Cell-Therapy | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03726515) CART-EGFRvIII + Pembrolizumab in GBM | |||
| REF 2 | ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.